232 related articles for article (PubMed ID: 31670945)
1. Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity.
Xu Y; Han X; Li Y; Min H; Zhao X; Zhang Y; Qi Y; Shi J; Qi S; Bao Y; Nie G
ACS Nano; 2019 Nov; 13(11):13445-13455. PubMed ID: 31670945
[TBL] [Abstract][Full Text] [Related]
2. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
3. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis.
Li M; Tang Z; Zhang Y; Lv S; Li Q; Chen X
Acta Biomater; 2015 May; 18():132-43. PubMed ID: 25735801
[TBL] [Abstract][Full Text] [Related]
5. Achieving traceless ablation of solid tumors without recurrence by mild photothermal-chemotherapy of triple stimuli-responsive polymer-drug conjugate nanoparticles.
Du C; Ding Y; Qian J; Zhang R; Dong CM
J Mater Chem B; 2019 Jan; 7(3):415-432. PubMed ID: 32254729
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Targeting of Differentiated Breast Cancer Cells and Breast Cancer Stem Cells by Combination of Docetaxel- and Sulforaphane-Loaded Self-Assembled Poly(D, L-lactide-co-glycolide)/Hyaluronic Acid Block Copolymer-Based Nanoparticles.
Huang J; Tao C; Yu Y; Yu F; Zhang H; Gao J; Wang D; Chen Y; Gao J; Zhang G; Zhou G; Liu J; Sun Z; Sun D; Zou H; Xu H; Lu Y; Zhong Y
J Biomed Nanotechnol; 2016 Jul; 12(7):1463-77. PubMed ID: 29337484
[TBL] [Abstract][Full Text] [Related]
8. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation.
Yu H; Tang Z; Li M; Song W; Zhang D; Zhang Y; Yang Y; Sun H; Deng M; Chen X
J Biomed Nanotechnol; 2016 Jan; 12(1):69-78. PubMed ID: 27301173
[TBL] [Abstract][Full Text] [Related]
12. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.
Li Q; Zhan M; Chen W; Zhao B; Yang K; Yang J; Yi J; Huang Q; Mohan M; Hou Z; Wang J
Oncotarget; 2016 Mar; 7(9):10271-82. PubMed ID: 26848531
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-loaded polymeric complex micelles with a modulated drug/copolymer ratio for improved in vivo performance.
Chen Q; Luo L; Xue Y; Han J; Liu Y; Zhang Y; Yin T; Wang L; Cun D; Gou J; He H; Tang X
Acta Biomater; 2019 Jul; 92():205-218. PubMed ID: 31071475
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates.
Di Pasqua AJ; Hong C; Wu MY; McCracken E; Wang X; Mi L; Chung FL
Chem Res Toxicol; 2010 Aug; 23(8):1307-9. PubMed ID: 20707406
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
16. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance.
Ling X; Chen X; Riddell IA; Tao W; Wang J; Hollett G; Lippard SJ; Farokhzad OC; Shi J; Wu J
Nano Lett; 2018 Jul; 18(7):4618-4625. PubMed ID: 29902013
[TBL] [Abstract][Full Text] [Related]
17. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
18. Near-infrared light stimuli-responsive synergistic therapy nanoplatforms based on the coordination of tellurium-containing block polymer and cisplatin for cancer treatment.
Li F; Li T; Cao W; Wang L; Xu H
Biomaterials; 2017 Jul; 133():208-218. PubMed ID: 28441615
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
